Clinical Trial: NCT05383716
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Peking Union Medical College Hospital |
| Information Provided By: | Peking Union Medical College Hospital |
| Last Update Posted: | 2024-04-23 |
Study Overview
Brief Summary
A phase II, single-arm, open-label study evaluating feasibility, safety and efficacy of combined chemotherapy and pembrolizumab as neoadjuvant/adjuvant therapy in stage IIa-IIIB NSCLC adult patients followed by adjuvant PD-(L)1 inhibitor treatment for up to 1 year
Official Title
A Prospective, Single-arm PhaseⅡTrial of Neoadjuvant/Adjuvant Pembrolizumab Plus Platinum-doublet Chemotherapy (Chemo) in IIa-IIIb NSCLC
Conditions
Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
Intervention / Treatment
- Drug: Pembrolizumab
Other Study ID Numbers
- ZS-2847
Start Date (Actual)
2022-07-01
Primary Completion Date (Actual)
2023-12-08
Study Completion Date (Estimated)
2027-12
Enrollment (Actual)
80
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Peking Union Medical College Hospital |
| Information Provided By: | Peking Union Medical College Hospital |
| Last Update Posted: | 2024-04-23 |
Study Overview
Brief Summary
A phase II, single-arm, open-label study evaluating feasibility, safety and efficacy of combined chemotherapy and pembrolizumab as neoadjuvant/adjuvant therapy in stage IIa-IIIB NSCLC adult patients followed by adjuvant PD-(L)1 inhibitor treatment for up to 1 year
Official Title
A Prospective, Single-arm PhaseⅡTrial of Neoadjuvant/Adjuvant Pembrolizumab Plus Platinum-doublet Chemotherapy (Chemo) in IIa-IIIb NSCLC
Conditions
Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
Intervention / Treatment
- Drug: Pembrolizumab
Other Study ID Numbers
- ZS-2847
Start Date (Actual)
2022-07-01
Primary Completion Date (Actual)
2023-12-08
Study Completion Date (Estimated)
2027-12
Enrollment (Actual)
80
Study Type
Interventional
Phase
Phase 2